Blueprint Medicines Corporation has announced the presentation of new data on the long-term clinical efficacy and safety profile of AYVAKIT®/AYVAKYT® (avapritinib) at the 2025 European Hematology Association (EHA2025) Hybrid Congress in Milan, Italy, and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, United Kingdom. These presentations, including one oral and two flash talks, highlight Blueprint Medicines' ongoing efforts to improve treatment for patients with systemic mastocytosis $(SM)$. The data underscore AYVAKIT's role as a durable standard of care for both indolent and advanced SM, and emphasize the real-world burden of the disease. The findings are based on patient data from the PIONEER, PATHFINDER, and EXPLORER trials, with follow-up extending up to five years for indolent SM and 6.5 years for advanced SM. The data presentations are available on the company's website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.